Top 10 Highlights of the Year at C Ray Therapeutics

As one year gives way to the next, a new chapter unfolds.

Looking back on 2025, C Ray Therapeutics has advanced side by side with all our partners. Guided by our commitment to high quality, high efficiency, and full compliance, we have delivered integrated one-stop services to support our partners in overcoming critical milestones from research and development to clinical translation. 

Over the Past Year: Top 10 Milestones

 The fully automated production line successfully supported first-in-patient dosing for the Phase III clinical trial of Maidenuo, ensuring a stable and reliable supply of clinical material.

C RAY Therapeutics Supports Mednovo’s Phase III Clinical Trial with First Patient Dosed for Lutetium [Lu-177] Oxodotreotide Injection-C-Ray Therapeutics

 Completed process development and registration-batch manufacturing for Baili Tianheng's first in-house developed ARC candidate within seven months, effectively supporting IND approval.

Domestically Developed Innovative ARC Enters Clinical Stage, Ushering in the Era of China's Self-Developed Radiopharmaceuticals-C-Ray Therapeutics

 Achieved large-scale production of Cu-64, with a batch capacity exceeding 2 Ci (post-EOB), and supported a project that obtained FDA IND clearance.

产能超2Ci，通瑞生物又创新高-C-Ray Therapeutics

 Realised fully automated, end-to-end production of Zr-89, becoming one of the few domestic companies with established supply capabilities.

C-RAY Achieves Breakthrough in Medical Isotope Production with China's First Fully Automated Zr-89 Process-C-Ray Therapeutics

 Obtained the first domestic regulatory filing approval for a self-developed radiopharmaceutical transport container, addressing a long-standing industry logistics challenge.

​​​​​C-RAY Therapeutics’ Innovation Breakthrough: China’s First NNSA-Approved Class II Radiopharmaceutical Transport Container Design-C-Ray Therapeutics

 Commissioned new Lu-177 and F-18 production lines, further strengthening integrated theranostics manufacturing capacity.

C Ray Expands Theranostics Platform with New Lu-177 and F-18 Production Lines-C-Ray Therapeutics

 Secured a licence for road transportation of radiopharmaceuticals, establishing a temperature-controlled "land–air integrated" logistics network covering nationwide delivery within 24–48 hours and extending across the Asia–Pacific region.

Re-Certification Achieved: C-RAY Enhances Radiopharmaceutical Transport Capabilities-C-Ray Therapeutics​​​​​​​

 Took the lead in establishing an industry innovation alliance, fostering a collaborative ecosystem for coordinated development across the value chain.

【LOOK!】Future XDC Drug Innovation Conference-C-Ray Therapeutics

 Entered a new phase of internationalisation, strengthening global connectivity within the radiopharmaceutical innovation landscape.

 EANM 2025 | Connecting Global Innovation, C Ray Accelerates Its Globalization Journey-C-Ray Therapeutics

 Successfully secured CRDMO's first overseas contract and achieved consecutive follow-on agreements, marking international recognition of the capability and quality of the Company's one-stop service platform and representing a solid step forward in global business expansion.

Every milestone is built on trust and collaboration; every breakthrough points towards a broader horizon.

As the curtain rises on 2026, C Ray Therapeutics will remain true to its original mission. With a stronger platform and enhanced services, we are committed to empowering our global partners to navigate the critical transitions from research to clinical development and on to commercial-scale production.